Trial | NCT00352339  Report issue

Title

The New Strategy for Pharmacological Treatment in People With Schizophrenia
Switch Risperidone to Aripiprazole in Early Stage of Pharmacotherapy of Schizophrenia

  • Phase

    Phase 4

  • Study Type

    Interventional

  • Status

    Unknown status

  • Study Participants

    90
Switching from Risperidone to Aripiprazole in early stage of pharmacotherapy will demonstrate the same efficacy as compared to risperidone continuation treatment in the treatment of schizophrenia.
It has been thought that D2 Blocking agent is necessary in acute as well as maintenance phase of pharmacological treatment of patients with schizophrenia. However, this classical strategy produces long term adverse events of drug such as TD, osteoporosis and some metabolic syndrome. To overcome these adverse events, new strategy for pharmacological treatment is needed.
Study Started
Aug 31
2006
Primary Completion
Dec 31
2010
Anticipated
Study Completion
Dec 31
2010
Anticipated
Last Update
Aug 06
2009
Estimate

Drug Rispridoen and Aripiprazole

Start with risperidone and switch it to aripiprazole. Flexible dose

Drug Risperidne

Start with risperidne and keep it through the end of study. Risperidne:flexible dose

Drug Abilify

Start with abilify and keep it through the end of study

  • Other names: abilify is a generic name of aripiprazole

Aripiprazole Experimental

switching group (from risperidone to aripiprazole)

Risperidone Active Comparator

Start with risperidone and keep it through the end of study

Abilify Active Comparator

Start with aripiprazole and keep it through the end of study

Criteria 

Inclusion Criteria:

Schizophrenia, DSM-IV
Acute phase

Exclusion Criteria:

Refractory Schizophrenia
Substance Abuse
High risk for suicide
No Results Posted